- Home
- PIM vs VYGR Comparison
PIM vs VYGR Comparison
Compare PIM & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- VYGR
- Stock Information
- Founded
- PIM 1988
- VYGR 2013
- Country
- PIM United States
- VYGR United States
- Employees
- PIM N/A
- VYGR N/A
- Industry
- PIM Finance Companies
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- VYGR Health Care
- Exchange
- PIM Nasdaq
- VYGR Nasdaq
- Market Cap
- PIM 160.9M
- VYGR 156.0M
- IPO Year
- PIM N/A
- VYGR 2015
- Fundamental
- Price
- PIM $3.32
- VYGR $2.97
- Analyst Decision
- PIM
- VYGR Strong Buy
- Analyst Count
- PIM 0
- VYGR 8
- Target Price
- PIM N/A
- VYGR $14.33
- AVG Volume (30 Days)
- PIM 57.5K
- VYGR 841.7K
- Earning Date
- PIM 01-01-0001
- VYGR 08-05-2025
- Dividend Yield
- PIM 8.28%
- VYGR N/A
- EPS Growth
- PIM N/A
- VYGR N/A
- EPS
- PIM 0.05
- VYGR N/A
- Revenue
- PIM N/A
- VYGR $66,958,000.00
- Revenue This Year
- PIM N/A
- VYGR N/A
- Revenue Next Year
- PIM N/A
- VYGR $78.88
- P/E Ratio
- PIM $63.80
- VYGR N/A
- Revenue Growth
- PIM N/A
- VYGR N/A
- 52 Week Low
- PIM $2.90
- VYGR $2.65
- 52 Week High
- PIM $3.28
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- PIM 47.33
- VYGR 41.86
- Support Level
- PIM $3.30
- VYGR $3.24
- Resistance Level
- PIM $3.34
- VYGR $3.64
- Average True Range (ATR)
- PIM 0.03
- VYGR 0.27
- MACD
- PIM -0.00
- VYGR -0.02
- Stochastic Oscillator
- PIM 18.75
- VYGR 6.17
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.